

Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology

Rudolf P. Talens,* Dorret I. Boomsma,[§] Elmar W. Tobi,* Dennis Kremer,* J. Wouter Jukema,[†] Gonneke Willemsen,[§] Hein Putter,[‡] P. Eline Slagboom,*^{||} and Bastiaan T. Heijmans*^{||,1}

*Department of Molecular Epidemiology, [†]Department of Cardiology, and [‡]Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands; [§]Department of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands; and ^{||}Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands

ABSTRACT The prospect of finding epigenetic risk factors for complex diseases would be greatly enhanced if DNA from existing biobanks, which is generally extracted from whole blood, could be used to perform epigenetic association studies. We characterized features of DNA methylation at 16 candidate loci, 8 of which were imprinted, in DNA samples from the Netherlands Twin Register biobank. Except for unmethylated or fully methylated sites, CpG methylation varied considerably in a sample of 30 unrelated individuals. This variation remained after accounting for the cellular heterogeneity of blood. Methylation of CpG sites was correlated within loci and, for 4 imprinted loci, across chromosomes. In 34 additional individuals, we investigated the DNA methylation of 8 representative loci in 2 longitudinal blood and 2 longitudinal buccal cell samples (follow-up 11–20 and 2–8 yr, respectively). Five of 8 loci were stable over time ($\rho > 0.75$) in both tissues, indicating that prospective epigenetic studies may be possible. For 4 loci, the DNA methylation in blood (mesoderm) correlated with that in the buccal cells (ectoderm) ($\rho > 0.75$). Our data suggest that epigenetic studies on complex diseases may be feasible for a proportion of genomic loci provided that they are carefully designed.—Talens, R. P., Boomsma, D. I., Tobi, E. W., Kremer, D., Jukema, J. W., Willemsen, G., Putter, H., Slagboom, P. E., Heijmans, B. T. Variation, patterns, and temporal stability of DNA methylation: considerations for epigenetic epidemiology. *FASEB J.* 24, 3135–3144 (2010). www.fasebj.org

Key Words: epigenome • biobank • human studies • complex disease

EPIGENETICS REFERS TO HERITABLE differences in gene expression potential that are not caused by variation in the DNA sequence (1, 2). Its molecular basis is the chemical modification of either the DNA itself (cytosine methylation in CpG dinucleotides) or the histones that package the chromatin (*e.g.*, methylation, acetylation, phosphorylation.) (3–5). It has frequently been proposed that changes in these epigenetic marks sig-

nificantly contribute to the risk of complex diseases, including cancer, cardiovascular, and metabolic disease (1, 6–10). However, with the exception of studies on cancer, empirical data from epidemiological studies supporting these hypotheses are largely absent, mainly due to technical and methodological limitations.

Many of the technical limitations have been resolved, in particular, with respect to the high-throughput measurement of DNA methylation (11, 12). DNA methylation is correlated with other layers of epigenetic marks, particularly histone modifications (13). DNA methylation may be the most suitable epigenetic mark for large-scale epidemiological studies, since methyl groups are covalently bound to CpG dinucleotides and are not lost during routine DNA extraction, unlike histone modifications. This opens the possibility of exploiting existing DNA biobanks for research purposes, to discover epigenetic risk factors for complex disease.

Epigenetic studies will require the development of data resources analogous to those that facilitated genetic association studies. The resources should include epigenome maps charting DNA methylation marks (14), the description of interindividual variation in DNA methylation (*cf.* single nucleotide polymorphisms and copy number variants) (15), and data on the patterns within this variation (*cf.* linkage disequilibrium) (16). To guide the development of such epigenome-wide resources, candidate loci may be studied. In this respect, differentially methylated regions influencing imprinting (17), transposon-derived sequences (17), CpG island shores (18), and recognition sequences for methylation-dependent transcription factors (19) are of particular interest.

In addition, several issues potentially limiting the use of existing biobanks for epigenetic epidemiology need to be addressed. First, DNA in biobanks is mostly extracted from whole blood, which, like any tissue,

¹ Correspondence: Molecular Epidemiology, Leiden University Medical Center, Postal Zone S-05-P, PO box 9600, 2300RC, Leiden, NL. E-mail: b.t.heijmans@lumc.nl
doi: 10.1096/fj.09-150490

consists of different cell types that may carry different epigenetic marks and whose relative numbers may vary between individuals (20). Second, the stability of DNA methylation over time should be known before the association of DNA methylation with future disease risk can be assessed. Global (or average) DNA methylation has been reported to change over time (21, 22), but DNA methylation of specific loci may be more stable (16, 23). Finally, it will be crucial to address the extent to which DNA methylation measured in blood is a marker for less accessible tissues that are directly involved in disease. Despite scattered reports that this may be the case (24–26), the issue remains largely unresolved.

We assessed whether genomic DNA stored in existing biobanks would be suitable for epigenetic epidemiological studies. To this end, we addressed the interindividual variation in DNA methylation of 16 candidate loci for cardiovascular and metabolic disease, the influence of blood cell heterogeneity on this variation, the stability of DNA methylation over time, and its correlation between whole blood (mesoderm) and buccal cells (ectoderm) in individuals from the Netherlands Twin Register (NTR) (27, 28).

MATERIALS AND METHODS

Study populations

The individuals investigated in this study were selected from the Netherlands Twin Register (NTR) biobank (27, 28), which includes DNA samples from Dutch twins and their family members (parents, siblings, offspring, and spouses). First, unrelated individuals were selected ($n=30$; Supplemental Table 3) to study interindividual variation in DNA methylation, the influence of cell heterogeneity, and patterns of DNA methylation. These 30 individuals were selected from the ongoing NTR biobank project for which 9560 individuals were included. Random selection would result in a sample of individuals with characteristics very close to the average in the complete cohort. For this, we applied the D-optimality crite-

rior to the Fisher information matrix, which enabled us to select 30 individuals representative of the whole range of phenotypic variation in age and metabolic parameters present in the complete cohort. The age of the individuals selected ranged from 21 to 73 yr; metabolic parameters of interest included waist circumference, fasting blood glucose level, serum LDL, and HDL cholesterol. Plasma and serum measurements and cell counts of whole blood were obtained using the standardized methods previously described (missing cell count information for 2/30 individuals). Furthermore, we selected the proportion of males to females and of those who had never been smokers, to former and current smokers, so that it was equal to the proportion in the complete cohort.

Second, 34 individuals were selected for assessing the correlation of DNA methylation across time and tissue and for validating the findings on the group of 30 individuals described above. This group consisted of participants in the NTR biobank project, who also took part in previous NTR projects. This allowed for recent DNA samples from whole blood (with information of cell counts) and buccal cells, as well as previous DNA samples from whole blood drawn 11 to 20 yr earlier, and from buccal swabs taken 2 to 8 yr earlier (Supplemental Table 4). The age at first sampling ranged from 14 to 62 yr. Among the 34 individuals, 17 were male, 26 were unrelated individuals, and 8 were included as 4 monozygotic twin pairs. DNA from all samples was extracted from whole blood and buccal swabs using standard methods.

Third, the results on within-individual correlation between CpG units were validated using 60 controls (28 males, mean age 57 yr) from the Dutch Hunger Winter Families Study (29). DNA methylation was measured at the same loci using the same methods as used in the current study (30, 31).

DNA methylation

Loci were selected on the basis of their potential involvement in cardiovascular and metabolic disease through the role of the adjacent candidate gene in growth, lipid metabolism, energy metabolism, inflammation, or stress response. Assay design focused on the regions of these loci that contained features with a potential for epigenetic regulation as observed in human, animal, or cell culture experiments (19, 24, 32–44). The loci selected included promoter elements, CpG

TABLE 1. Characteristics of methylation assays

Locus	Chromosome	Megabase	Gene function	CpG sites ^a	Single CpG sites ^b	Imprinted	CpG-island
<i>IL10^c</i>	01q32.1	205.01	Anti-inflammation	4	2		
<i>NR3C1</i>	05q31.3	142.67	Stress response	20	4		+
<i>TNF</i>	06p21.33	31.65	Proinflammatory	8	5		
<i>IGF2R^c</i>	06q25.3	160.35	Growth/apoptosis	10	0	?	+
<i>GRB10</i>	07p12.2	50.82	IIS inhibitor	16	5	+	+
<i>LEP^c</i>	07q32.1	127.67	Metabolism	10	5		+
<i>CRH^c</i>	08q13.1	67.25	Stress response	5	5		
<i>ABCA1</i>	09q31.1	106.73	Cholesterol transport	16	3		+
<i>IGF2^c</i>	11p15.5	2.13	Early growth	5	3	+	
<i>INSIGF^c</i>	11p15.5	2.14	Embryonic growth	4	4	?	
<i>KCNQ1OT1^c</i>	11p15.5	2.68	Imprinting control region	14	7	+	+
<i>MEG3</i>	14q32.2	100.36	Growth suppressor	7	3	+	+
<i>FTO</i>	16q12.2	52.38	Development	10	4		
<i>APOC1^c</i>	19q13.32	50.11	Metabolism	6	6		
<i>GNASAS</i>	20q13.32	56.86	Growth/lypolytic signal	17	3		
<i>GNAS A/B</i>	20q13.32	56.90	Growth/lypolytic signal	12	3	+	+

^aCpG sites that met the quality criteria described in Materials and Methods. ^bCpG sites of which the methylation proportion was measured individually. ^cMethylation-sensitive transcription factor-binding sites. ^dCpG methylation previously reported to associate with gene expression. ^eStability across time and correlation between tissues were also investigated.

islands, transposon-derived sequences, methyl-sensitive transcription factor binding sites (mTFBS), imprinted differentially methylated regions (DMR), and regions reported to regulate transcription through DNA methylation. Methylation assays were designed using the methprimer tool (45) on sections of sequence downloaded from the University of California, Santa Cruz genome browser (46). Fifty-eight assays were tested for the reliability of the methylation measurement. Forty assays gave a reliable measurement, and on the basis of the priority given to the associated candidate gene and epigenetic properties (Table 1), 16 of these were selected to cover the whole range of possible average methylation levels (0–100%).

One microgram of genomic DNA was bisulfite-converted using the EZ 96-DNA methylation (Zymo Research, Orange, CA, USA). DNA of the 30 individuals, in whom variation in DNA methylation was investigated, was converted on a single 96-well plate. DNA methylation of all 16 loci was measured using the same bisulfite-converted sample. The 4 samples (blood, buccal, recent, and old) from individuals selected for testing the correlation over time and across tissues were bisulfite-treated on the same 96-well plate. For this substudy, two 96-well plates were used to process the 136 samples, each plate with an equal number of individuals. Methylation of the 8 loci was measured using a single bisulfite-converted DNA sample. Primers used to amplify the region of each assay are given in Supplemental Table 5A. DNA methylation was measured using a mass spectrometry-based method (Epityper; Sequenom, San Diego, CA, USA) (47), whose quantitative accuracy (R^2 duplicate measurements ≥ 0.98) and concordance with clonal PCR bisulfite sequencing was reported previously (48, 49). All measurements were done in triplicate. Quality control consisted of several steps. CpG site-containing fragments that had equal or overlapping mass, making them irresolvable by mass spectrometry, and CpG sites containing fragments whose measurement was confounded by single-nucleotide polymorphisms (16) according to dbSNP build 128 were discarded (Supplemental Table 6). Next, at least 2 of the 3 replicate measurements had to be successful, and the SD of the replicate measurements had to be ≤ 0.10 . Only CpG sites with a success rate $>75\%$ for the latter two criteria were considered fit for further analysis, and the average was calculated for the replicate measurements. With these criteria applied, DNA methylation of 164 CpG sites, distributed over 104 CpG site-containing fragments (CpG units; ref. 47), could

be measured in the first sample of 30 individuals (Supplemental Table 5B); 62 CpG units contained 1 CpG site, 28 CpG units contained 2 CpG sites, 10 CpG units contained 3 CpG sites, and 4 CpG units contained 4 CpG sites. The methylation of multiple CpG sites occurring on one fragment (CpG unit) cannot be resolved individually. Average CpG methylation for these CpG units was calculated using the RSeqMeth module (48). The average success rate for the 104 CpG units assessed was 97%. In the second sample of 34 individuals, 41 CpG units containing 55 CpG sites could be measured, applying the same criteria only to the recent blood samples and 38 CpG units containing 52 CpG sites to all 4 samples (Supplemental Table 5C).

To exclude the influence of DNA sequence variation not present in dbSNP on higher correlations observed between DNA methylation measured on a recent and an old sample and on a blood and a buccal swab sample, the evaluateSNPs() function of the R-module MassArray was used (50). The Epityper method for DNA methylation measurements is based on a protocol to resequence genomic DNA using mass spectrometry (MassCleave; Sequenom) (51). By comparing the mass spectrum observed with the one expected according to a reference sequence, data points can be identified that are suspected of being confounded by sequence variation. This interference can be direct when the sequence variant affects a fragment containing a CpG site or indirect when the sequence variant changes the mass of a non-CpG fragment so that it overlaps with a CpG-containing fragment. It is noteworthy that sequencing genomic DNA would deal with direct interference only. Data points suspected to be affected by unknown sequence variation were excluded, and correlations were recalculated to examine their influence. CpG measurements were removed for *APOC1*, CpG 1 [4 individuals excluded for all DNA samples (recent, old, blood, buccal)], CpG 10 (8 exclusions) and CpG 11 (11 exclusions); *LEP*, CpG 8 (1 exclusion); *IGF2*, CpG 6–7 (21 exclusions); *IGF2R*, CpG 4–5 (1 exclusion), and CpG 11–13 (4 exclusions); for *CRH*, no measurements were excluded.

Statistical analyses

Variation in DNA methylation

CpG sites with average methylation levels close to 0 or 100% by definition have a truncated variance. To circumvent this

TABLE 1. (continued)

Promoter	Intragenic	Intergenic	Putative mTFBS ^c	Confirmed mTFBS ^c	Transposon	Literature ^d
+			3	6	+	+(32)
+			3	2		+(19)
+			2			+(34)
+	+		1			+(35)
+			4	2		+(36)
+				3		+(37)
+			1	1		+(38)
+			4	4		±(39)
+	+		2			+(24)
+						+(40)
+			1	1		+(41)
+	+					+(42)
		+	3		+	±(43)
+				1		+(44)
+						+(33)

problem, the following variance-stabilizing transformation was applied (52): Transformed value = $\text{Arc tan} \{[\text{methylation}/(1 - \text{methylation})]^2\}$. Using the transformed values, we tested the equality of the variance of CpG sites with Levene's test.

Accounting for cellular heterogeneity

To test whether variation in DNA methylation was confounded by cellular heterogeneity, nested linear mixed models (53) were applied to the transformed data. The basic model was created as a baseline, to be subtracted from the nested models. It included the CpG site as a fixed effect. The 3 nested models each had one percentage of a major white blood cell subclass, namely neutrophils, lymphocytes, or monocytes, added to the basic model as an extra fixed effect to test whether variation in this percentage could explain part of the variation in DNA methylation. The actual amount of variation in DNA methylation that could be explained by the percentage of the white blood cell type was calculated as 100% minus the percentage of the residual variance of the nested model with respect to the residual variance of the basic model. The linear mixed model accounts for correlated methylation within individuals and deals with methylation data missing at random without imputation (30). It may be seen as an extension of the paired *t* test: the model will reduce to a paired *t* test with identical results if between-group methylation differences are assessed for a single CpG site and if data are complete and all other factors are omitted.

Correlation and patterns of CpG methylation

Bivariate Pearson correlation coefficients between CpG sites were calculated after adjusting the transformed methylation levels for neutrophil percentage. Nonsignificant correlations were treated as if there were no correlations (value of correlation set to 0). Patterns in the correlation matrix were visualized with a heat map after unsupervised complete linkage clustering, which utilizes the Euclidean distance (the difference between two points in the matrix squared).

Stability over time

The difference between DNA methylation at two time points was calculated per individual for each CpG unit as methylation of the old sample minus methylation of the new sample. Missing values were excluded pairwise. Spearman's rank correlation coefficient (ρ) was used to calculate the correlation between the two time points.

Correlation between tissues

The difference between DNA methylation in blood and buccal cells was calculated per individual for each CpG unit as methylation of the recent blood sample minus methylation of the recent buccal cell sample. Missing values were excluded pairwise. Spearman's ρ was used to calculate the correlation between the two tissues.

Male and female data were analyzed separately in every test. However, in view of the study size, the outcomes of these analyses should be considered as purely explorative. All *P* values are 2-sided, and statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Interindividual variation in DNA methylation

We quantitatively measured the DNA methylation of 16 candidate loci using DNA samples from the NTR biobank, to estimate the variation in the general population. The DNA was extracted from whole blood. The DNA samples were from 30 unrelated individuals, who were selected to represent the broad range in age and metabolic parameters of the whole biobank. After removing CpGs, for which local genetic polymorphisms could interfere with DNA methylation measurements, and CpGs that did not meet the quality criteria, we recorded methylation of 164 CpG sites, distributed over 104 CpG units, of which 62 contained a single CpG site (Table 1). The average methylation of the loci studied ranged from 0 to 98% (Fig. 1). Within the majority of loci, the average methylation of CpG sites was similar. Exceptions were *LEP*, with a 34% methylation difference between CpG sites located 18 bases apart, and *ABCA1*, with a 31% difference between sites 26 bases apart. Previous studies reported methylation differences between men and women (31, 54). We could not detect such differences in an explorative analysis. This may be related to the study size and the number of tests performed.

A considerable interindividual variation in CpG methylation was observed. The variation approximated a normal distribution except for CpG units that showed no or very little variation (average DNA methylation close to 0 or 100%). The extent of this variation varied per CpG unit ($0 < \text{SD} < 15\%$). To exclude the possibility that this difference in variation might merely be due to the fact that DNA methylation is truncated at 0 and 100%, a variance stabilizing transformation was applied (52). The variation remained significantly different between CpG units ($P = 10^{-16}$). To validate these findings, we measured the DNA methylation of 8 of 16 loci (55 CpG sites, 31 CpG units with 1 CpG site) in 34 additional individuals from the NTR biobank, and this yielded similar results (Supplemental Fig. 1).

Cellular heterogeneity

DNA methylation was measured on genomic DNA extracted from whole blood. As whole blood consists of different cell types, which may display differences in DNA methylation, we tested the extent to which the interindividual variation observed was influenced by cellular heterogeneity, as assessed by counting the major cell subclasses. The largest cellular fraction consisted of neutrophils (average proportion $53.7 \pm 8.8\%$), thus contributing the majority of DNA molecules on which CpG methylation was analyzed. For 10 of 16 loci, the variation in DNA methylation was not associated with this measure of cellular heterogeneity (Table 2). For the remaining loci, the variation in DNA methylation that could be explained by variation in cellular heterogeneity was generally small, and associations were of borderline significance. *IL10*, which is highly expressed in leukocytes, was a notable exception: 50%




Figure 1. Interindividual variation in DNA methylation. Methylation percentage, y axis, at every CpG unit, x axis, for each of the 30 individuals, colored dots. Order of the loci is based on their chromosomal location, starting at the lowest designation. CpG unit numbers are counted from the forward primer onwards. Name of each locus is given below the x axis. Bold horizontal bar gives the median; thin horizontal bars show the interquartile range for each CpG unit. Vertical lines across the plot separate the loci. Corresponding CpG sites of each CpG unit are given in Supplemental Table 5B. Individually measured CpG sites are marked with an S below the unit number.

of its variation in DNA methylation could be attributed to the neutrophil cell count. The analysis was repeated using the lymphocyte percentage (average proportion $34.4 \pm 8.4\%$), which was highly correlated with the neutrophil percentage ($r = -0.95$), and similar results were observed (data not shown). No influence of monocyte percentage was observed on DNA methylation (average $8.0 \pm 1.8\%$; correlation with the neutrophil proportion: $r = -0.48$). The influence of cellular heterogeneity was not affected by gender (data not shown).

To validate these findings, we performed the same test on the 8 loci in an additional 34 individuals (Supplemental Table 1). The loci previously not showing an association were again not associated with the neutrophil percentage (*IGF2R*, *IGF2*, *INSGF*, and *KCNQ1OT1*). Two of the associations of borderline significance were not found (*APOC1* and *CRH*), but the modest association of *LEP* with the neutrophil percentage was replicated ($P = 1.0 \times 10^{-4}$). Again, a substantial proportion of the variation in *IL10* methylation could be attributed to the neutrophil percentage (27.9%, $P = 8.0 \times 10^{-8}$).

Correlations and patterns of CpG methylation

To investigate patterns of DNA methylation further within and across loci, correlations between the methylation of CpG sites were computed and visualized using a heat map after unsupervised clustering (Fig. 2). CpG methylation was particularly correlated within loci ($r_{\max} = 0.95$) but also across loci ($r_{\max} = 0.68$). The cluster of loci correlating irrespectively of chromosomal location included paternally imprinted loci (*MEG3* and *GNASAS*) and maternally imprinted loci (*GRB10*, *KCNQ1OT1*, and *GNAS A/B*). These observations were unaffected by variance-stabilizing transformation or adjustment for cell heterogeneity prior to analysis (data not shown).

The correlation was studied for the same 16 loci in 60 controls of the Dutch Hunger Winter Families Study that we measured previously (30, 31). The heat map of the correlations revealed similar patterns (Supplemental Fig. 2). Again, a strong correlation was observed within loci. Across loci, significant correlations were observed for *GNASAS*, *GNAS A/B*, *GRB10*, and *MEG3*. In addition, a correlation between these loci and *IGF2* was observed,

TABLE 2. Association of neutrophil proportion with DNA methylation

Locus	Variance explained (%)	P value of effect
<i>IL10</i>	50.1	3.9×10^{-06}
<i>NR3C1</i>	0.2	0.555
<i>TNF</i>	8.0	0.037
<i>IGF2R</i>	5.0	0.208
<i>GRB10</i>	0.7	0.625
<i>LEP</i>	7.4	0.019
<i>CRH</i>	4.0	0.022
<i>ABCA1</i>	7.3	0.021
<i>IGF2</i>	3.5	0.185
<i>INSIGF</i>	0.3	0.674
<i>KCNQ1OT1</i>	0.4	0.733
<i>MEG3</i>	4.1	0.165
<i>FTO</i>	0.1	0.714
<i>APOC1</i>	6.2	0.026
<i>GNASAS</i>	0.8	0.590
<i>GNAS A/B</i>	0.0	0.889

whereas the correlation with *KCNQ1OT1* was not reproduced. The correlations were similar for both sexes (data not shown).

Stability over time

To study the stability of DNA methylation over time, we selected 34 additional individuals from the NTR for whom two blood samples were taken 11–20 yr apart. The methylation of 8 loci that were representative of the set of 16 loci was measured (Table 1). Overall, DNA methylation was similar at the two time points (Fig. 3A), and only minor differences were observed (Table 3). Similar average methylation levels between the time points do not indicate stability *per se* since methylation may increase in some and decrease in other individuals


over time. The variation around the average difference was greatest for *IL10*, which also showed the greatest average difference ($-2.8 \pm 9.1\%$; Table 3). It was lowest for *KCNQ1OT1* ($SD=2.8\%$), indicating relative stability over time. An alternative way to express stability, which takes into account the differences in interindividual variation of the loci, is to compute correlation coefficients (Table 3). For 5 of the 8 loci, the correlation $\rho > 0.75$ indicated substantial stability between the time points. These loci included *IGF2R* ($\rho=0.88$) and *APOC1* ($\rho=0.96$). Note that the correlation was low for *KCNQ1OT1* ($\rho=0.31$), which can be attributed to the very low level of interindividual variation. Temporal stability was similar in both sexes (data not shown). From the same 34 individuals, DNA samples from buccal swabs taken 2–8 yr apart were available and showed similar results (Supplemental Table 2).

To exclude the possibility that the higher correlations observed were due to sequence variation not present in dbSNP, we used the mass spectra to identify CpG methylation measurements that were suspected to have been influenced by sequence variation (50). This was the case for 1 or more individuals for 7/41 CpG units. Removal of these CpG measurements did not affect the correlations $\rho > 0.75$ (*IGF2R*, $\rho=0.87$; *LEP*, $\rho=0.90$; *IGF2*, $\rho=0.92$; *CRH*, $\rho=0.94$; and *APOC1*, $\rho=0.95$).

Correlation of CpG methylation between tissues

To test whether DNA methylation in blood could mark that in other tissues, we studied DNA methylation of the 8 loci in the recent blood (mesoderm) and buccal swab (ectoderm) samples of the individuals in whom stability over time was tested. The average level of DNA methylation was generally different between the two tissues and the extent of the difference depended on the locus (Fig. 3B, Table 4). The variation around the average

Figure 2. Correlation between CpG sites within and across loci. Heat map depicting correlations between the methylation levels of all CpG units of the 16 loci measured in the first sample of 30 individuals. For reference, the CpG units are annotated by a color, based on the locus (key at right). Diagonal axis running from bottom left to top right corner is the line of symmetry where each CpG unit hypothetically correlates with itself. Full correlation ($=1$) is plotted as the brightest red shade; full inverse correlation ($=-1$) is plotted as the brightest green shade; no correlation ($=0$) is plotted as black (key at top left). Nonsignificant correlations are depicted as no correlation. Complete clustering is based on the Euclidean distance.






Figure 3. Temporal stability and comparison between blood and buccal cell DNA methylation. Scatterplots for individual comparison of CpG methylation between the DNA samples. CpG units of each individual are annotated by coloring based on the locus. Diagonal $x = y$ line is plotted in black for reference. *A*) CpG methylation in the first blood sample (x axis) is plotted against methylation in the second, more recent, blood sample (y axis). *B*) CpG methylation in the recent blood DNA sample (x axis) is plotted against methylation in the recent buccal swab DNA sample (y axis). Each dot represents 1 CpG unit of 1 individual in both DNA samples.

difference also varied per locus. Again, *IL10* showed the highest variation ($SD=17.1$), and *KCNQ1OT1* showed the lowest ($SD=3.0$). For all loci, the SD of the average difference between the tissues was higher than that of the average difference between the time points. For 4 of the 8 loci, the correlation of DNA methylation

between the two tissues was >0.75 . These loci included *IGF2R* ($\rho=0.83$) and *APOC1* ($\rho=0.82$). Again, the correlations were similar in both sexes (data not shown). After removing CpGs measurements suspected to be influenced by sequence variation not present in dbSNP, similar correlations were found (*IGF2R*, $\rho=0.82$; *LEP*, $\rho=0.80$; *CRH*, $\rho=0.90$; and *APOC1*, $\rho=0.81$).

DISCUSSION

Epigenetic risk factors are thought to contribute to the development of common diseases such as cardiovascular and metabolic disease (6, 9, 10). Here, we investigated whether genomic DNA from existing biobanks is suitable for the identification of these risk factors in epidemiological studies (1, 7).

Using genomic DNA from the Netherlands Twin Register biobank (27, 28), we first assessed the interindividual variation in DNA methylation for 16 candidate loci, since the human epigenome map is still in development (14), and epigenome-wide resources on variation (*i.e.*, the epivariome) are lacking. We observed considerable variation in CpG methylation between individuals, except for loci that are either not methylated or fully methylated. The extent of this variation varied between CpG sites. Earlier reports frequently characterized CpG methylation as hypomethylation, isomethylation, or hypermethylation (24, 55). Our data support our own previous work (16) and that of others (15) in which DNA methylation was more accurately described as a quantitative trait.

Second, we addressed the possibility that the variation in DNA methylation could simply be attributed to cellular heterogeneity in leukocytes between individuals (20). Blood, like any tissue, consists of a mixture of different cell types that all may have a cell-specific epigenome (3). Our results show that for the large majority of candidate loci, interindividual differences in the cellular composition of the blood sample did not contribute to the variation observed in DNA methylation or explained only a minor proportion of this variation. One notable exception was the *IL10* locus, for which cellular heterogeneity explained up to half of the total variation in DNA methylation. If cell counts are available for whole blood samples stored in a biobank, the potentially confounding influence of cel-

TABLE 3. Comparison of DNA methylation in blood samples of the two time points

Locus	Methylation (%)		Difference (%)	Spearman's ρ
	Old blood	New blood		
<i>IL10</i>	22.4 \pm 9.0	25.2 \pm 6.6	-2.8 \pm 9.1	0.422
<i>IGF2R</i>	65.8 \pm 16.8	67.6 \pm 17.7	-1.8 \pm 8.1	0.883
<i>LEP</i>	20.0 \pm 11.5	21.8 \pm 13.0	-1.8 \pm 6.1	0.895
<i>CRH</i>	63.4 \pm 22.1	63.8 \pm 21.1	-0.4 \pm 6.7	0.942
<i>IGF2</i>	49.4 \pm 11.8	49.0 \pm 11.3	0.4 \pm 4.7	0.924
<i>INSIGF</i>	86.4 \pm 4.1	85.5 \pm 4.3	0.9 \pm 3.7	0.649
<i>KCNQ1OT1</i>	30.8 \pm 2.2	31.8 \pm 2.6	-1.0 \pm 2.8	0.307
<i>APOC1</i>	19.7 \pm 11.4	19.6 \pm 11.7	0.1 \pm 3.4	0.956

Values are means \pm SD.

TABLE 4. Comparison of DNA methylation in recent blood and buccal cell samples

Locus	Methylation (%)			Spearman's ρ
	Blood	Buccal cells	Difference (%)	
<i>IL10</i>	24.8 \pm 7.1	64.9 \pm 18.8	-40.1 \pm 17.1	0.442
<i>IGF2R</i>	68.3 \pm 17.4	81.6 \pm 12.4	-13.3 \pm 10.6	0.827
<i>LEP</i>	21.7 \pm 13.7	11.8 \pm 8.8	9.9 \pm 9.9	0.798
<i>CRH</i>	63.8 \pm 21.9	58.4 \pm 21.4	5.4 \pm 7.9	0.905
<i>IGF2</i>	48.8 \pm 11.5	32.4 \pm 11.0	16.4 \pm 10.8	0.557
<i>INSIGF</i>	85.4 \pm 4.3	84.4 \pm 4.7	1.0 \pm 4.6	0.371
<i>KCNQ1OT1</i>	32.0 \pm 2.6	34.7 \pm 3.1	-2.7 \pm 3.0	0.481
<i>APOC1</i>	19.9 \pm 11.7	10.7 \pm 9.6	9.2 \pm 7.6	0.822

Values are means \pm SD.

lular heterogeneity can be monitored using standard statistical methods. If no data on cellular heterogeneity are available, it may be necessary to exclude the association of cellular heterogeneity either with the outcome of interest or with methylation of the locus studied. The latter can be addressed, for example, in a substudy for which data on leukocyte populations are available. Our study suggests that no such relationship will be observed for many loci, in which case biobanks without data on cellular heterogeneity may still be useful.

Third, we investigated patterns in CpG methylation within and across loci. We found that within the locus, CpG methylation is highly correlated, except for candidate loci that were not methylated or fully methylated, which corroborates recent findings (16, 56). This observation suggests that assessing the methylation of a subset of CpGs is sufficient to cover the variation in DNA methylation at a locus. This is analogous to genetic association studies in which a small number of tagging SNPs can cover all genetic variation at a locus due to linkage disequilibrium (57). Moreover, our results provide the first indication that methylation of CpG sites can also be correlated irrespective of their chromosomal location. This was observed for a subset of mainly imprinted loci, which may be related to the mechanisms responsible for establishing methylation marks at DMRs (58, 59).

Fourth, since DNA methylation is a reversible process (60), it may not be stable over time. If so, this would preclude conclusions about causality in epidemiological studies, since DNA methylation may change during a follow-up period. The majority of loci tested were stable over time in DNA from blood and buccal cells despite possible changes in cellular composition during the follow-up period. The fact that we investigated DNA samples that were taken 11 to 20 yr apart, implies that these DNA methylation marks may be investigated in most prospective cohort studies in which participants are followed for the development of disease for similar or shorter follow-up periods. However, for a minority of loci, we found that although, on average, there was no difference in DNA methylation between the time points, the correlation was lower, indicating relaxed maintenance of these DNA methylation marks. This data resemble recent results on global DNA methylation studying similar follow-up periods (22). The age of the individuals in our study was limited to young and middle ages (14 to 62 yr old). Therefore, we cannot exclude instability over very

long periods of time, nor can we exclude the occurrence of greater changes in old age. Indeed, instability of the DNA methylation marks in old age has been reported for both locus-specific (23, 30) and global (61) DNA methylation. Moreover, our study did not address the possible occurrence of changes in DNA methylation as a consequence of disease or processes preceding its clinical manifestation (62).

DNA from existing biobanks generally is extracted from easily accessible tissues such as blood. Future studies may reveal DNA methylation patterns in such tissues that mark the risk of disease. As a first step toward establishing a possible causal role, it will be necessary to determine that DNA methylation measured in peripheral tissues is associated with that in tissues directly involved in the disease of interest. Although DNA methylation is thought to be a mechanism driving cell differentiation leading to tissue-specific differentially methylated regions (18), initial reports indicated that DNA methylation measured in blood may be informative. For example, *IGF2* and *ER- α* methylation in blood marked that of colon tissue (24, 25). Also, an autopsy study of 6 subjects and 11 tissues, which did not include blood, suggested that the hypomethylation and hypermethylation status of loci is commonly preserved across tissues (26). Comparing the methylation of candidate loci in blood and buccal cells, we found that for half of the loci tested, DNA methylation measured in blood was a marker for that in buccal cells. These results are promising, since blood and buccal cells stem from different germ layers (mesoderm and ectoderm, respectively) and warrant the investigation of correlations with other tissues involved in disease. Genome-scale studies in particular, will be informative for defining the (sequence) characteristics of loci showing correlations across tissues. Such studies will be required to interpret the results of epidemiological studies on DNA methylation in blood in a meaningful way.

Our study on the suitability of DNA from existing biobanks for epigenetic studies provides leads for setting up new biobanks specifically aimed at epigenetic epidemiology. Since the correlation between DNA methylation, as measured in DNA from blood and other tissues (directly involved in disease), appears to be complex and locus-dependent, such initiatives should ideally include efforts to sample tissues others than blood (mesoderm), at least for a subgroup representing the cohort. Tissues representing the three germ layers for which collection is feasible include the mesoderm: biopsies of skeletal mus-

cle, subcutaneous fat and the dermal layer of a skin punch biopsy (fibroblasts); the ectoderm: the epidermal layer of a skin punch biopsy (keratinocytes) and buccal cells; and the endoderm: a urine sample (bladder lining) and a stool sample (colonic mucosa). In addition, follow-up sampling of the various tissues should be included (at least for a subgroup) to assess temporal stability and changes in DNA methylation as a consequence of pathology. To account for the cellular heterogeneity of blood samples, blood cell populations should be counted if whole blood is biobanked. This can easily be done using cheap, routine methods. An alternative approach to reduce the cellular heterogeneity is to store peripheral blood mononuclear cells (PBMCs) instead of whole blood. PBMCs include lymphocytes (T and B cells) and monocytes, while the granulocytes (mainly neutrophils) are lost. To completely remove cellular heterogeneity, cells can be separated using magnetic-activated cell sorting (MACS). However, this is exceedingly costly and will not be feasible for larger numbers in most projects.

Taken together, our results indicate that there are good prospects for the use of existing biobanks for epigenetic studies. Loci that are suitable for testing in epigenetic studies demonstrate interindividual variation in DNA methylation, stability of this variation in DNA methylation over time, and a correlation between DNA methylation as measured in blood and the tissue of interest. Our data shows that meeting these criteria is locus-dependent. Therefore, it may be necessary to address these aspects for each combination of locus, tissue, and disease in new studies. FJ

The authors thank Dr. L. H. Lumey (Mailman School of Public Health, Columbia University, New York, NY, USA), for access to the Dutch Hunger Winter Family Study samples used in our analysis. This work was supported by grants from the Netherlands Heart Foundation (NHS2006B083); the Netherlands Organization for Scientific Research (NWO); the twin-family database for behavior genomics studies (480-04-004, 911-03-016); Spinozapremie (SPI 56-464-14192); the Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI) and the Centre for Neurogenomics and Cognitive Research (CNCR-VU); genome-wide analyses of European twin and population cohorts (EU/QLRT-2001-01254); the European Union-funded Network of Excellence LifeSpan (FP6 036894); and the NGI/NWO-funded Netherlands Consortium for Healthy Ageing (050 60 810).

REFERENCES

- Waterland, R. A., and Michels, K. B. (2007) Epigenetic Epidemiology of the developmental origins hypothesis. *Annu. Rev. Nutr.* **27**, 363–388
- Jaenisch, R., and Bird, A. (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat. Genet.* **33**(Suppl.), 245–254
- Suzuki, M. M., and Bird, A. (2008) DNA methylation landscapes: provocative insights from epigenomics. *Nat. Rev. Genet.* **9**, 465–476
- Kouzarides, T. (2007) Chromatin modifications and their function. *Cell* **128**, 693–705
- Kouzarides, T. (2007) SnapShot: histone-modifying enzymes. *Cell* **128**, 802
- Petronis, A. (2001) Human morbid genetics revisited: relevance of epigenetics. *Trends Genet.* **17**, 142–146
- Foley, D. L., Craig, J. M., Morley, R., Olsson, C. J., Dwyer, T., Smith, K., and Saffery, R. (2009) Prospects for epigenetic epidemiology. *Am. J. Epidemiol.* **169**, 389–400
- Feinberg, A. P. (2008) Epigenetics at the epicenter of modern medicine. *JAMA* **299**, 1345–1350
- Pons, D., de Vries, F. R., van den Elsen, P. J., Heijmans, B. T., Quax, P. H., and Jukema, J. W. (2009) Epigenetic histone acetylation modifiers in vascular remodeling: new targets for therapy in cardiovascular disease. *Eur. Heart. J.* **30**, 266–277
- Turunen, M. P., Aavik, E., and Yla-Herttuala, S. (2009) Epigenetics and atherosclerosis. *Biochim. Biophys. Acta* **1790**, 886–891
- Shen, L., and Waterland, R. A. (2007) Methods of DNA methylation analysis. *Curr. Opin. Clin. Nutr. Metab. Care* **10**, 576–581
- Smith, Z. D., Gu, H., Bock, C., Gnirke, A., and Meissner, A. (2009) High-throughput bisulfite sequencing in mammalian genomes. *Methods* **48**, 226–232
- Bernstein, B. E., Meissner, A., and Lander, E. S. (2007) The mammalian epigenome. *Cell* **128**, 669–681
- Lister, R., Pelizzola, M., Downen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., Nery, J. R., Lee, L., Ye, Z., Ngo, Q. M., Edsall, L., ntosiewicz-Bourget, J., Stewart, R., Ruotti, V., Millar, A. H., Thomson, J. A., Ren, B., and Ecker, J. R. (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* **462**, 315–322
- Rakyan, V. K., Hildmann, T., Novik, K. L., Lewin, J., Tost, J., Cox, A. V., Andrews, T. D., Howe, K. L., Otto, T., Olek, A., Fischer, J., Gut, I. G., Berlin, K., and Beck, S. (2004) DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. *PLoS Biol.* **2**, e405
- Heijmans, B. T., Kremer, D., Tobi, E. W., Boomsma, D. I., and Slagboom, P. E. (2007) Heritable rather than age-related environmental and stochastic factors dominate variation in DNA methylation of the human IGF2/H19 locus. *Hum. Mol. Genet.* **16**, 547–554
- Waterland, R. A., and Jirtle, R. L. (2003) Transposable elements: targets for early nutritional effects on epigenetic gene regulation. *Mol. Cell. Biol.* **23**, 5293–5300
- Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., Gabo, K., Rongione, M., Webster, M., Ji, H., Potash, J. B., Sabuncuyan, S., and Feinberg, A. P. (2009) The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. *Nat. Genet.* **41**, 178–186
- Weaver, I. C., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., and Meaney, M. J. (2004) Epigenetic programming by maternal behavior. *Nat. Neurosci.* **7**, 847–854
- Martin, G. M. (2005) Epigenetic drift in aging identical twins. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 10413–10414
- Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., Heine-Suner, D., Cigudosa, J. C., Urioste, M., Benitez, J., Boix-Chornet, M., Sanchez-Aguilera, A., Ling, C., Carlsson, E., Poulsen, P., Vaag, A., Stephan, Z., Spector, T. D., Wu, Y. Z., Plass, C., and Esteller, M. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 10604–10609
- Bjornsson, H. T., Sigurdsson, M. I., Fallin, M. D., Irizarry, R. A., Aspelund, T., Cui, H., Yu, W., Rongione, M. A., Ekstrom, T. J., Harris, T. B., Launer, L. J., Eiriksdottir, G., Leppert, M. F., Sapienza, C., Gudnason, V., and Feinberg, A. P. (2008) Intra-individual change over time in DNA methylation with familial clustering. *JAMA* **299**, 2877–2883
- Ito, Y., Koessler, T., Ibrahim, A. E., Rai, S., Vowler, S. L., bu-Amero, S., Silva, A. L., Maia, A. T., Huddleston, J. E., Uribe-Lewis, S., Woodfine, K., Jagodic, M., Nativio, R., Dunning, A., Moore, G., Klenova, E., Bingham, S., Pharoah, P. D., Brenton, J. D., Beck, S., Sandhu, M. S., and Murrell, A. (2008) Somatic acquired hypomethylation of IGF2 in breast and colorectal cancer. *Hum. Mol. Genet.* **17**, 2633–2643
- Cui, H., Cruz-Correa, M., Giardiello, F. M., Hutcheon, D. F., Kafonek, D. R., Brandenburg, S., Wu, Y., He, X., Powe, N. R., and Feinberg, A. P. (2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. *Science* **299**, 1753–1755
- Ally, M. S., Al-Ghannani, R., and Pufulete, M. (2009) The relationship between gene-specific DNA methylation in leukocytes and normal colorectal mucosa in subjects with and without colorectal tumors. *Cancer Epidemiol. Biomarkers Prev.* **18**, 922–928
- Byun, H. M., Siegmund, K. D., Pan, F., Weisenberger, D. J., Kanel, G., Laird, P. W., and Yang, A. S. (2009) Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. *Hum. Mol. Genet.* **18**, 4808–4817

27. Boomsma, D. I., de Geus, E. J., Vink, J. M., Stubbe, J. H., Distel, M. A., Hottenga, J. J., Posthuma, D., van Beijsterveldt, T. C., Hudziak, J. J., Bartels, M., and Willemsen, G. (2006) Netherlands Twin Register: from twins to twin families. *Twin Res. Hum. Genet.* **9**, 849–857
28. Boomsma, D. I., Willemsen, G., Sullivan, P. F., Heutink, P., Meijer, P., Sondervan, D., Klufft, C., Smit, G., Nolen, W. A., Zitman, F. G., Smit, J. H., Hoogendijk, W. J., van, D. R., de Geus, E. J., and Penninx, B. W. (2008) Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. *Eur. J. Hum. Genet.* **16**, 335–342
29. Lumey, L., Stein, A. D., Kahn, H. S., van der Pal-de Bruin, K. M., Blauw, G., Zybert, P. A., and Susser, E. S. (2007) Cohort profile: the Dutch Hunger Winter Families Study. *Int. J. Epidemiol.* **36**, 1196–1204
30. Heijmans, B. T., Tobi, E. W., Stein, A. D., Putter, H., Blauw, G. J., Susser, E. S., Slagboom, P. E., and Lumey, L. H. (2008) Persistent epigenetic differences associated with prenatal exposure to famine in humans. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 17046–17049
31. Tobi, E. W., Lumey, L. H., Talens, R. P., Kremer, D., Putter, H., Stein, A. D., Slagboom, P. E., and Heijmans, B. T. (2009) DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. *Hum. Mol. Genet.* **18**, 4046–4053
32. Dong, J., Ivascu, C., Chang, H. D., Wu, P., Angeli, R., Maggi, L., Eckhardt, F., Tykocinski, L., Haefliger, C., Mowes, B., Sieper, J., Radbruch, A., Annunziato, F., and Thiel, A. (2007) IL-10 is excluded from the functional cytokine memory of human CD4⁺ memory T lymphocytes. *J. Immunol.* **179**, 2389–2396
33. Hayward, B. E., Kamiya, M., Strain, L., Moran, V., Campbell, R., Hayashizaki, Y., and Bonthron, D. T. (1998) The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 10038–10043
34. Sullivan, K. E., Reddy, A. B., Dietzmann, K., Suriano, A. R., Kocieda, V. P., Stewart, M., and Bhatia, M. (2007) Epigenetic regulation of tumor necrosis factor alpha. *Mol. Cell. Biol.* **27**, 5147–5160
35. Sandovici, I., Leppert, M., Hawk, P. R., Suarez, A., Linares, Y., and Sapienza, C. (2003) Familial aggregation of abnormal methylation of parental alleles at the IGF2/H19 and IGF2R differentially methylated regions. *Hum. Mol. Genet.* **12**, 1569–1578
36. Arnaud, P., Monk, D., Hitchins, M., Gordon, E., Dean, W., Beechey, C. V., Peters, J., Craigen, W., Preece, M., Stanier, P., Moore, G. E., and Kelsey, G. (2003) Conserved methylation imprints in the human and mouse GRB10 genes with divergent allelic expression suggests differential reading of the same mark. *Hum. Mol. Genet.* **12**, 1005–1019
37. Melzner, I., Scott, V., Dorsch, K., Fischer, P., Wabitsch, M., Bruderlein, S., Hasel, C., and Moller, P. (2002) Leptin gene expression in human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its proximal promoter. *J. Biol. Chem.* **277**, 45420–45427
38. McGill, B. E., Bundle, S. F., Yaylaoglu, M. B., Carson, J. P., Thaller, C., and Zoghbi, H. Y. (2006) Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 18267–18272
39. Probst, M. C., Thumann, H., Aslanidis, C., Langmann, T., Buechler, C., Patsch, W., Baralle, F. E., Dallinga-Thie, G. M., Geisel, J., Keller, C., Menys, V. C., and Schmitz, G. (2004) Screening for functional sequence variations and mutations in ABCA1. *Atherosclerosis* **175**, 269–279
40. Adkins, R. M., Fain, J. N., Krushkal, J., Klauser, C. K., Magann, E. F., and Morrison, J. C. (2007) Association between paternally inherited haplotypes upstream of the insulin gene and umbilical cord IGF-II levels. *Pediatr. Res.* **62**, 451–455
41. Mitsuya, K., Meguro, M., Lee, M. P., Katoh, M., Schulz, T. C., Kugoh, H., Yoshida, M. A., Niikawa, N., Feinberg, A. P., and Oshimura, M. (1999) LIT1, an imprinted antisense RNA in the human KvLQT1 locus identified by screening for differentially expressed transcripts using monochromosomal hybrids. *Hum. Mol. Genet.* **8**, 1209–1217
42. Rosa, A. L., Wu, Y. Q., Kwabi-Addo, B., Coveler, K. J., Reid, S. V., and Shaffer, L. G. (2005) Allele-specific methylation of a functional CTCF binding site upstream of MEG3 in the human imprinted domain of 14q32. *Chromosome Res.* **13**, 809–818
43. Medstrand, P., Landry, J. R., and Mager, D. L. (2001) Long terminal repeats are used as alternative promoters for the endothelin B receptor and apolipoprotein C-I genes in humans. *J. Biol. Chem.* **276**, 1896–1903
44. Hayward, B. E., and Bonthron, D. T. (2000) An imprinted antisense transcript at the human GNAS1 locus. *Hum. Mol. Genet.* **9**, 835–841
45. Li, L. C., and Dahiya, R. (2002) MethPrimer: designing primers for methylation PCRs. *Bioinformatics* **18**, 1427–1431
46. Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., and Haussler, D. (2002) The human genome browser at UCSC. *Genome Res.* **12**, 996–1006
47. Ehrich, M., Nelson, M. R., Stanssens, P., Zabeau, M., Liloglou, T., Xinarianos, G., Cantor, C. R., Field, J. K., and van den Boom, D. (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15785–15790
48. Coolen, M. W., Statham, A. L., Gardiner-Garden, M., and Clark, S. J. (2007) Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements [Online]. *Nucleic Acids Res.* **35**, e119
49. Ehrich, M., Turner, J., Gibbs, P., Lipton, L., Giovanneti, M., Cantor, C., and van den Boom, D. (2008) Cytosine methylation profiling of cancer cell lines. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 4844–4849
50. Thompson, R. F., Suzuki, M., Lau, K. W., and Grealley, J. M. (2009) A pipeline for the quantitative analysis of CG dinucleotide methylation using mass spectrometry. *Bioinformatics* **25**, 2164–2170
51. Stanssens, P., Zabeau, M., Meersseman, G., Remes, G., Gansemans, Y., Storm, N., Hartmer, R., Honisch, C., Rodi, C. P., Bocker, S., and van den Boom, D. (2004) High-throughput MALDI-TOF discovery of genomic sequence polymorphisms. *Genome Res.* **14**, 126–133
52. Altman, D. G. (1991) *Practical Statistics for Medical Research*, Chapman and Hall, London
53. West, B., Welch, K., and Galecki, A. (2006) *Linear Mixed Models: A Practical Guide Using Statistical Software*, Chapman Hall/CRC Press, Boca Raton, FL, USA
54. El-Maari, O., Becker, T., Junen, J., Manzoor, S. S., az-Lacava, A., Schwaab, R., Wienker, T., and Oldenburg, J. (2007) Gender-specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. *Hum. Genet.* **122**, 505–514
55. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 9821–9826
56. Bock, C., Walter, J., Paulsen, M., and Lengauer, T. (2008) Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping [Online]. *Nucleic Acids Res.* **36**, e55
57. The International HapMap Consortium (2003) The International HapMap Project. *Nature* **426**, 789–796
58. Bourc'his, D., Xu, G. L., Lin, C. S., Bollman, B., and Bestor, T. H. (2001) Dnmt3L and the establishment of maternal genomic imprints. *Science* **294**, 2536–2539
59. Ooi, S. K., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., Tempst, P., Lin, S. P., Allis, C. D., Cheng, X., and Bestor, T. H. (2007) DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. *Nature* **448**, 714–717
60. Ramchandani, S., Bhattacharya, S. K., Cervoni, N., and Szyf, M. (1999) DNA methylation is a reversible biological signal. *Proc. Natl. Acad. Sci. U. S. A.* **96**, 6107–6112
61. Bollati, V., Schwartz, J., Wright, R., Litonjua, A., Tarantini, L., Suh, H., Sparrow, D., Vokonas, P., and Baccarelli, A. (2009) Decline in genomic DNA methylation through aging in a cohort of elderly subjects. *Mech. Ageing Dev.* **130**, 234–239
62. Heijmans, B. T., Tobi, E. W., Lumey, L. H., and Slagboom, P. E. (2009) The epigenome: Archive of the prenatal environment. *Epigenetics* **4** 526–531

Received for publication November 24, 2009.
Accepted for publication March 18, 2010.